The reaction to a potential COVID-19 vaccine breakthrough for young children out of Moderna (MRNA) may have some traders scratching their heads.
Shares of the biotech fell 3% on Wednesday on positive interim data released by Moderna for its coronavirus vaccine for children under six years old. Moderna said the shots were about 44% effective in preventing Omicron in children six months up to two years old.
“We believe these latest results from the KidCOVE study are good news for parents of…
Source link
